Cytek Biosciences, Inc. — Director's Dealing 2021

Jul 23, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Cytek BioSciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2021-07-22

Reporting Person: DENG FENG (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (147933)		Indirect
Series C Preferred Stock	$		Common Stock (4168777)		Indirect
Series D Preferred Stock	$		Common Stock (443800)		Indirect

Footnotes

F1: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.

F2: Shares held directly by Northern Light Venture Capital V, Ltd. ("NLVC V"). Fund V serves as the nominee for each of Northern Light Venture Fund V, L.P., Northern Light Strategic Fund V, L.P. and Northern Light Partners Fund V, L.P (together, the "NLVC V Funds"). Northern Light Partners V, L.P., a Cayman Islands exempted limited liability partnership, is the general partner of the NLVC V Funds. NLVC V is the general partner of Northern Light Partners V, L.P. Feng Deng is the controlling shareholder of NLVC V and may be deemed to have voting and dispositive power with respect to the shares held by NLVC V.